1. Home
  2. ELF vs PBLS Comparison

ELF vs PBLS Comparison

Compare ELF & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo e.l.f. Beauty Inc.

ELF

e.l.f. Beauty Inc.

HOLD

Current Price

$63.18

Market Cap

3.0B

ML Signal

HOLD

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$27.54

Market Cap

3.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ELF
PBLS
Founded
2004
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.2B
IPO Year
2016
2026

Fundamental Metrics

Financial Performance
Metric
ELF
PBLS
Price
$63.18
$27.54
Analyst Decision
Strong Buy
Analyst Count
17
0
Target Price
$111.88
N/A
AVG Volume (30 Days)
4.1M
N/A
Earning Date
05-27-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.44
N/A
Revenue
$1,636,472,000.00
N/A
Revenue This Year
$23.87
N/A
Revenue Next Year
$17.15
N/A
P/E Ratio
$145.91
N/A
Revenue Growth
24.59
N/A
52 Week Low
$48.82
N/A
52 Week High
$150.99
N/A

Technical Indicators

Market Signals
Indicator
ELF
PBLS
Relative Strength Index (RSI) 57.29 N/A
Support Level $58.05 N/A
Resistance Level $71.23 N/A
Average True Range (ATR) 3.77 0.00
MACD 1.35 0.00
Stochastic Oscillator 65.36 0.00

Price Performance

Historical Comparison
ELF
PBLS

About ELF e.l.f. Beauty Inc.

e.l.f. Beauty Inc is a multi-brand beauty company that offers inclusive, accessible, clean, vegan, and cruelty-free cosmetics and skin care products. The Company's mission is to make beauty accessible to every eye, lip, face, and skin concern. The company offers cosmetic accessories for women, which include eyeliner, mascara, false eyelashes, lipstick, foundation for the face, moisturizer, cleanser, and other tools through its stores and e-commerce channels.

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Share on Social Networks: